---
title: "VK2735 in Chronic weight management: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on VK2735 in Chronic weight management: Place in treatment, anticipated use, and care setting. Topics: Summary: anticipated place in treatment, Preferred pharmacotherapy in people with diabetes and overweight or obesity, Obesity as a chronic disease requiring lifelong care, Primary care as the care setting, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: anticipated place in treatment

VK2735 is investigational and has no approved indication. Guidelines place anti-obesity pharmacotherapy as an adjunct to lifestyle intervention: the AGA strongly recommends pharmacotherapy in addition to lifestyle intervention for adults with BMI of 30 or higher, or 27 or higher with weight-related complications, who have an inadequate response to lifestyle interventions, and the ADA names semaglutide or tirzepatide as the preferred agents for people with diabetes and overweight or obesity. The WHO guideline describes obesity as requiring “lifelong care”. The OMA and ACOFP describe family physicians as “often the first line of treatment”, and ICER expects that “much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians”. Viking describes the subcutaneous formulation as suited to weight maintenance with every-other-week or monthly dosing after weekly induction, and the VANQUISH-1 extension will include these less-frequent regimens, with results anticipated in 2028. Viking describes the oral tablet as positioned to become the first oral dual GLP-1/GIP agonist to reach the market and expects many initial users of oral therapies to transition to subcutaneous administration. In a May 2024 national poll, 12% of U.S. adults reported ever taking a GLP-1 agonist and 6% reported current use.

Source: [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/); [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/); [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/); [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Montero et al. (2024)](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/)

<a id="topic-2.2.2.2-2"></a>

### Preferred pharmacotherapy in people with diabetes and overweight or obesity

> “Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes. Potential benefits and risks must be considered.”
> “In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide)”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.2-3"></a>

### Obesity as a chronic disease requiring lifelong care

> “The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities.”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.2.2-4"></a>

### Primary care as the care setting

> “Family physicians are often the first line of treatment in the healthcare setting.”
> “Barriers that impede optimal care of patients with obesity in primary care include failure to recognize obesity as a disease, lack of accurate diagnosis, insufficient access to obesity treatment resources, inadequate training, insufficient time, lack of adequate reimbursement and the adverse impact of bias, stigma, and discrimination.”

Source: [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)

> “Given the large size of the population affected by obesity, much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians.”
> “there is a shortage of primary care physicians who are knowledgeable about treatment of obesity as well as an extreme shortage of obesity medicine specialists”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.2-5"></a>

### Subcutaneous formulation: manufacturer positioning for weight maintenance

> “As we have discussed previously, VK2735 has a unique and differentiated profile that we believe may accommodate less frequent dosing compared to standard weekly dosing, making it uniquely suited for the maintenance setting.”
> “Importantly, by using the same therapeutic agent for both the initial weight loss and for the long-term maintenance phase of weight management, we believe patients may experience reduced side effects compared with options that require switching between different therapeutic agents.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.2.2.2-6"></a>

### Subcutaneous formulation: less-frequent dosing regimens in the VANQUISH-1 extension

> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.2.2.2-7"></a>

### Oral formulation: manufacturer positioning

> “If successful, the tablet formulation is positioned to become the first oral dual GLP-1/GIP agonist to reach the market.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “As clinicians and patients continue to seek flexibility in formulations and dosing, we believe oral VK2735 may represent another differentiated and high-value tool in their treatment toolbox.”
> “What we are seeing right now with the oral therapies is sort of a market expansion. We expect a lot of those initial users to likely transition to the subQ route of administration to achieve even greater weight loss than they have experienced with the initial oral experience.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.2.2.2-8"></a>

### Oral and subcutaneous formulations: manufacturer positioning on dosing flexibility

> “The potential availability of both a tablet and a subcutaneous formulation, across a variety of dosing regimens, will offer unmatched optionality and flexibility to best support a personalized and sustainable weight loss journey.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Having the ability to dose weekly, every other week, or monthly, I think imparts flexibility that others cannot offer at this point and we do not see in the market today.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.2.2.2-9"></a>

### Use of GLP-1 agonists among U.S. adults

> “The latest KFF Health Tracking Poll finds that about one in eight adults (12%) say they have ever taken a GLP-1 agonist”
> “including 6% who say they are currently taking such a drug”

Source: [Montero et al. (2024)](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
